Abstract
On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty (R), BioNTech, Mainz, Germany;Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV-2 in the European Union and the second vaccine (Moderna (R), Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0340-1855 |
Sprache: | Deutsch |
Dokumenten ID: | 99180 |
Datum der Veröffentlichung auf Open Access LMU: | 05. Jun. 2023, 15:30 |
Letzte Änderungen: | 17. Okt. 2023, 15:00 |